Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 9/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.74 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.74 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.71 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.71 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.71 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.71 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.71 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.71 |
| ▸ | ACHE | P22303 | 1/20 | 0.57 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.51 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ibogamine SCHEMBL30443192 | 1.00 | SLC6A4 (1.00) | SLC6A4OPRM1OPRK1SIGMAR1CHRNB2 | |
| Ibogamine SCHEMBL31187082 | 1.00 | SLC6A4 (1.00) | SLC6A4OPRM1OPRK1SIGMAR1CHRNB2 | |
| Ibogamine SCHEMBL433382 | 1.00 | SLC6A4 (1.00) | SLC6A4OPRM1OPRK1SIGMAR1CHRNB2 | |
| Ibogamine SCHEMBL30045937 | 1.00 | SLC6A4 (1.00) | SLC6A4OPRM1OPRK1SIGMAR1CHRNB2 | |
| Ibogamine SCHEMBL17058953 | 1.00 | SLC6A4 (1.00) | SLC6A4OPRM1OPRK1SIGMAR1CHRNB2 | |
| Ibogamine SCHEMBL26728807 | 1.00 | SLC6A4 (1.00) | SLC6A4OPRM1OPRK1SIGMAR1CHRNB2 | |
| Ibogamine SCHEMBL433383 | 1.00 | SLC6A4 (1.00) | SLC6A4OPRM1OPRK1SIGMAR1CHRNB2 | |
| Ibogamine SCHEMBL9763817 | 0.99 | SLC6A4 (0.98) | SLC6A4OPRM1OPRK1SIGMAR1CHRNB2 | |
| Ibogamine SCHEMBL9763815 | 0.99 | SLC6A4 (0.98) | SLC6A4OPRM1OPRK1SIGMAR1CHRNB2 | |
| SCHEMBL8457238 | 0.87 | SLC6A4 (0.77) | SLC6A4OPRM1OPRK1SIGMAR1CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348465-A1 | IBOGAINE ANALOGS AS THERAPEUTICS FOR NEUROLOGICAL AND PSYCHIATRIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230348465-A1 | IBOGAINE ANALOGS AS THERAPEUTICS FOR NEUROLOGICAL AND PSYCHIATRIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-02 | — | — | US | disclosed |
| EP-3915639-B1 | METHODS AND COMPOSTIONS FOR POTENTIATING THE ACTION OF OPIOID ANALGESICS USING IBOGA ALKALOIDS | DEMERX INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-9617274-B1 | Synthetic noribogaine | DEMERX, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617274-B1 | Synthetic noribogaine | DEMERX, INC. (US) | 2017-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348465-A1 | IBOGAINE ANALOGS AS THERAPEUTICS FOR NEUROLOGICAL AND PSYCHIATRIC DISORDERS | CHRNA3, CHRNB3, CHRNA4 | SLC6A4 76/4885OPRM1 33/4885OPRK1 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.